XBiotech Announces Pricing of Public Offering of Common Shares
AUSTIN, Texas, May 31, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced the pricing of an underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share. The offering is expected to close on or about June 4, 2019, subject to the satisfaction of customary closing conditions.
In addition, XBiotech has granted the underwriter a 30-day option to purchase up to an additional 351,515 common shares at the public offering price, less underwriting discounts and commissions.
Piper Jaffray is acting as the sole underwriter in the offering.
XBiotech expects to receive gross proceeds of approximately $40 million. The proceeds of the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by XBiotech, will be used primarily to advance bermekimab Phase 2 clinical trials in Hidradenitis Suppurativa and Atopic Dermatitis, and for general corporate and working capital purposes.
The common shares are being issued and sold pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. A preliminary prospectus supplement and accompanying base prospectus relating to the offering, and a final prospectus supplement and accompanying base prospectus relating to the offering each contain important information relating to the XBiotech common shares. The preliminary prospectus supplement and accompanying base prospectus has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. The final prospectus supplement and accompanying base prospectus will be filed with the SEC and available on the SEC’s website thereafter, and may also be obtained, when available, by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email at email@example.com, or by phone at (800) 747-3924.
This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Notice of Extra General Meeting in Acarix AB15.7.2020 13:00:00 CEST | Press release
Notice of Extra General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the extra general meeting to be held on Tuesday 11 August 2020, at 10.00 at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm.. Information with respect to the coronavirus Due to the development of the coronavirus the goal is that the extra general meeting shall be swift and effective to minimize spread of disease. Shareholders should carefully consider the possibility to vote in advance, please see below, as well as the possibility of participating by way of proxy. Shareholders who display symptoms of infection (dry cough, fever, respiratory distress, sore throat, headache, muscle and joint ache), have been in contact with people displaying symptoms, have visited a risk area, or belong to a risk group, are in particular encouraged to utilize such possibility. The board of directors of the Company has resolved on the following measu
Kallelse till extra bolagsstämma i Acarix AB15.7.2020 13:00:00 CEST | Pressemelding
Kallelse till extra bolagsstämma i Acarix AB Aktieägarna i Acarix AB, org. nr 559009-0667, ("Bolaget") kallas härmed till extra bolagsstämma tisdagen den 11 augusti 2020 kl. 10.00 i Baker & McKenzie Advokatbyrås lokaler på Vasagatan 7 i Stockholm. Information med anledning av coronaviruset På grund av utvecklingen av coronaviruset är målsättningen att extra bolagsstämman ska bli kort och effektiv med minsta risk för smittspridning. Aktieägare bör noga överväga att använda sig av möjligheten att förhandsrösta, se nedan, samt möjligheten att delta genom ombud. Aktieägare som uppvisar symptom på smitta (torrhosta, feber, andningsbesvär, halsont, huvudvärk, muskel- och ledvärk), har varit i kontakt med personer som uppvisar symptom, har vistats i ett riskområde eller tillhör en riskgrupp, uppmanas särskilt att nyttja sig av sådan möjlighet. Bolagets styrelse har beslutat om följande åtgärder för att minimera risken för spridning av coronaviruset vid extra bolagsstämman: Möjligheten att för
AIR Collaborates with Precisely to Offer Clients Premium International Geocoding in Touchstone 202015.7.2020 12:13:10 CEST | Press release
Boston, July 15, 2020 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide today announced that as part of its Touchstone® 2020 software release, clients now have the ability to access a premium international address-level geocoding feature from Precisely, the global leader in data integrity, to enhance the quality of their exposure data. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “Using high quality exposure data, such as any information about the property, its replacement value, and its physical characteristics including the location of that property, has a significant impact on the loss results generated by a catastrophe model,” said Gayatri Natarajan, vice president of product, AIR Worldwide. “Having the right latitude and longitude coordinates for a property can have an enormous bearing upon the accuracy of risk estimation and the impact that extreme events might have on that property. Through our collaboration with Precisely, Touchstone 2020 will help support client
Medtronic to Acquire Medicrea15.7.2020 08:30:10 CEST | Press release
Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery DUBLIN and LYON, France, July 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of spinal surgery through artificial intelligence, predictive modeling and patient specific implants, today announced that they have entered into a tender offer agreement for the acquisition of all outstanding shares of Medicrea. The friendly voluntary all-cash tender offer will be at a price of €7.00 per Medicrea share (the “Tender Offer”). The Boards of Directors of both companies have unanimously approved the transaction. This acquisition would strengthen Medtronic’s position as a global innovator in enabling technologies and solutions for spine sur
Program for the publication of Yara International ASA second quarter results 202015.7.2020 08:00:00 CEST | Press release
The Yara International ASA second quarter 2020 report and presentation will be published on Friday 17 July 2020at08:00 CEST. An on-line presentation and Q&A session will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether, CFO Lars Røsæg, EVP Global Plants & Operational Excellence Pål Hestad and EVP Farming Solutions Terje Knutsen. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: yara.com/investor-relations/latest-quarterly-report/ Yours faithfully for Yara International ASA Thor Giæver Head of Investor Relations About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable value growth, promoting climate-friendly and high-yielding crop nutrition solutions for the world’s farming community and food industry. Yara’s ambition is to be the Crop Nutrition Company for the Future.
Program for offentliggjøring av Yara International ASA 2. kvartalsrapport 202015.7.2020 08:00:00 CEST | Pressemelding
Yara International ASAs resultatrapport og presentasjon for 2. kvartal 2020 offentliggjøres fredag 17. juli 2020kl. 08.00. Det vil holdes en nettbasert presentasjon og Q&A kl. 12.00. Resultatene vil presenteres av konsernsjef Svein Tore Holsether, finansdirektør Lars Røsæg, konserndirektør for Global plants & Operational Excellence Pål Hestad og konserndirektør for Farming Solutions Terje Knutsen. Presentasjonen vil bli holdt på engelsk. Resultatrapport, presentasjon og webcast vil være tilgjengelige til ovennevnte tider på: yara.com/investor-relations/latest-quarterly-report/ Med hilsen for Yara International ASA Thor Giæver Investorkontakt Om Yara Yara bringer kunnskap om hvordan verdens befolkning kan mettes og kloden beskyttes. Bak vår visjon om en verden uten sult ligger en strategi som fremmer klimavennlige og ressurseffektive løsninger for landbruk og matvareindustri over hele verden. Vår ambisjon er å være fremtidens leverandør av plantenæring. Vi har forpliktet oss til å skape